FOLH1 and renal cell carcinoma: Additionally, a retrospective study of 61 patients who underwent PSMA PET/CT for restaging or suspected metastatic RCC demonstrated PSMA PET-positive disease in 84% of patients, resulting in a change in management in 49% of patients [31].